AlphaSIP is a winner of the 2015 European Commission’s SME Instrument, which promotes the development of Europe’s best and most innovative SMEs. This novel funding scheme helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition. The SME Instrument has opened new possibilities for AlphaSIP, greatly accelerating the development of our new product range and increasing our chances of succeeding in the medical market.

Thanks to this award, AlphaSIP will receive 3,4M € to complete the development of PneumoSIP, our amplification-based pneumonia kit and MultySIP, its associated one-stop diagnostic platform. The development phase is expected to end in 24 months, after clinical validation, making both elements ready for commercialization.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 685052